Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.61 |
| ▸ | MAP2K2 | P36507 | 14/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5390951 | 0.90 | MAP2K1 (0.76) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL5379574 | 0.87 | MEN1 (0.50) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL5388138 | 0.86 | MAP2K1 (0.60) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL5396229 | 0.86 | MAP2K1 (0.77) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL5391378 | 0.86 | MAP2K1 (0.55) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL7788875 | 0.84 | MAP2K1 (0.58) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL5391537 | 0.82 | MAP2K1 (0.49) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL5389165 | 0.81 | MAP2K1 (0.79) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL5393899 | 0.80 | MAP2K1 (0.66) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL5396108 | 0.79 | MAP2K1 (0.41) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169816-B2 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | claimed |
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY LLC | 2006-03-09 | — | — | US | claimed |
| US-6972298-B2 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor | WARNER-LAMBERT COMPANY (US) | 2005-12-06 | — | — | US | claimed |
| EP-1140291-B1 | COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR | WARNER LAMBERT CO (US) | 2005-11-23 | — | — | EP | claimed |
| EP-1140062-B1 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER LAMBERT CO (US) | 2005-04-06 | — | — | EP | claimed |
| EP-0993439-B1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2004-09-29 | — | — | EP | claimed |
| US-20040171632-A1 | Combination chemotherapy | GOWAN RICHARD CARLETON (US) | 2004-09-02 | — | — | US | claimed |
| US-20030078428-A1 | Phenylamino benzhydroxamic acid derivatives inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer, psoriasis and restenosis; inhibit the phosphorylation of MAP kinase by MEK | BARRETT STEPHEN DOUGLAS (US) | 2003-04-24 | — | — | US | claimed |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | BARAGI VIJAYKUMAR M (US) | 2003-03-20 | — | — | US | claimed |
| JP-2003504400-A | — | — | 2003-02-04 | — | — | JP | claimed |
| WO-2001005392-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2000037141-A9 | COMBINATION CHEMOTHERAPY | WARNER LAMBERT CO (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2000040237-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000040235-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000037141-A1 | COMBINATION CHEMOTHERAPY | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| WO-2000035436-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0993439-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | claimed |
| WO-1999001426-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078428-A1 | Phenylamino benzhydroxamic acid derivatives inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer, psoriasis and restenosis; inhibit the phosphorylation of MAP kinase by MEK | MAP2K2, MAP2K7, MAP2K1 | MAP2K1 3/4885MAP2K2 1/4885HDAC3 1633/4885 |
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BRAF, MAPK1, MAPK4 | MAP2K1 43/4885MAP2K2 36/4885HDAC3 835/4885 |
| US-20040171632-A1 | Combination chemotherapy | BUB1B, BUB1, PLK1 | MAP2K1 67/4885MAP2K2 48/4885HDAC3 661/4885 |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | MMP8, SERPINB1, CXCR2 | MAP2K1 105/4885MAP2K2 89/4885HDAC3 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.